Table of Contents Author Guidelines Submit a Manuscript
Journal of Nutrition and Metabolism
Volume 2011, Article ID 235389, 4 pages
http://dx.doi.org/10.1155/2011/235389
Research Article

Selective Glucocorticoid Receptor (GR-II) Antagonist Reduces Body Weight Gain in Mice

1Department of Cardiovascular Medicine, Stanford University, Stanford, CA 94305, USA
2Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, USA
3Corcept Therapeutics, Menlo Park, CA 94025, USA

Received 7 March 2011; Revised 26 April 2011; Accepted 27 April 2011

Academic Editor: Maria Luz Fernandez

Copyright © 2011 Tomoko Asagami et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. M. Flegal, M. D. Carroll, C. L. Ogden, and L. R. Curtin, “Prevalence and trends in obesity among US adults, 1999–2008,” Journal of the American Medical Association, vol. 303, no. 3, pp. 235–241, 2010. View at Publisher · View at Google Scholar · View at PubMed
  2. R. C. Andrews and B. R. Walker, “Glucocorticoids and insulin resistance: old hormones, new targets,” Clinical Science, vol. 96, no. 5, pp. 513–523, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. G. P. Chrousos, “The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes,” International Journal of Obesity, vol. 24, no. 2, pp. S50–S55, 2000. View at Publisher · View at Google Scholar
  4. D. N. Orth, “Medical progress: cushing's syndrome,” New England Journal of Medicine, vol. 332, no. 12, pp. 791–803, 1995. View at Publisher · View at Google Scholar · View at PubMed
  5. L. K. Nieman, B. M. K. Biller, J. W. Findling et al., “The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 5, pp. 1526–1540, 2008. View at Publisher · View at Google Scholar · View at PubMed
  6. P. Anagnostis, V. G. Athyros, K. Tziomalos, A. Karagiannis, and D. P. Mikhailidis, “The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 8, pp. 2692–2701, 2009. View at Publisher · View at Google Scholar · View at PubMed
  7. J. Lindholm, S. Juul, J. O. L. Jørgensen et al., “Incidence and late prognosis of Cushing's syndrome: a population-based study,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 1, pp. 117–123, 2001. View at Publisher · View at Google Scholar
  8. S. Dinneen, A. Alzaid, J. Miles, and R. Rizza, “Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans,” Journal of Clinical Investigation, vol. 92, no. 5, pp. 2283–2290, 1993. View at Google Scholar
  9. D. P. Rooney, R. D.G. Neely, C. Cullen et al., “The effect of cortisol on glucose/glucose-6-phosphate cycle activity and insulin action,” Journal of Clinical Endocrinology and Metabolism, vol. 77, no. 5, pp. 1180–1183, 1993. View at Publisher · View at Google Scholar
  10. R. A. Rizza, L. J. Mandarino, and J. E. Gerich, “Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action,” Journal of Clinical Endocrinology and Metabolism, vol. 54, no. 1, pp. 131–138, 1982. View at Google Scholar
  11. L. K. Nieman, G. P. Chrousos, and C. Kellner, “Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU486,” Journal of Clinical Endocrinology and Metabolism, vol. 61, pp. 536–540, 1985. View at Publisher · View at Google Scholar · View at PubMed
  12. B. M. K. Biller, A. B. Grossman, P. M. Stewart et al., “Treatment of adrenocorticotropin-dependent cushing's syndrome: a consensus statement,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 7, pp. 2454–2462, 2008. View at Publisher · View at Google Scholar · View at PubMed
  13. S. Johanssen and B. Allolio, “Mifepristone (RU 486) in Cushing's syndrome,” European Journal of Endocrinology, vol. 157, no. 5, pp. 561–569, 2007. View at Publisher · View at Google Scholar · View at PubMed
  14. X. Bertagna, C. Bertagna, M. H. Laudat, F. Girard, and J. P. Luton, “Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 63, no. 3, pp. 639–643, 1986. View at Google Scholar
  15. J. W. Chu, D. F. Matthias, J. Belanoff, A. Schatzberg, A. R. Hoffman, and D. Feldman, “Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486),” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 8, pp. 3568–3573, 2001. View at Publisher · View at Google Scholar
  16. F. Castinetti, M. Fassnacht, S. Johanssen et al., “Merits and pitfalls of mifepristone in Cushing's syndrome,” European Journal of Endocrinology, vol. 160, no. 6, pp. 1003–1010, 2009. View at Publisher · View at Google Scholar · View at PubMed
  17. C. Gross, C. M. Blasey, R. L. Roe, and J. K. Belanoff, “Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men,” Obesity, vol. 18, no. 2, pp. 2295–2300, 2010. View at Publisher · View at Google Scholar · View at PubMed
  18. C. Gross, C. M. Blasey, R. L. Roe, K. Allen, T. S. Block, and J. K. Belanoff, “Mifepristone treatment of olanzapine-induced weight gain in healthy men,” Advances in Therapy, vol. 26, no. 10, pp. 959–969, 2009. View at Publisher · View at Google Scholar · View at PubMed
  19. J. K. Belanoff, C. M. Blasey, R. D. Clark, and R. L. Roe, “Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain,” Diabetes, Obesity and Metabolism, vol. 12, no. 6, pp. 545–547, 2010. View at Publisher · View at Google Scholar · View at PubMed
  20. R. D. Clark, N. C. Ray, K. Williams et al., “1H-Pyrazolo[3,4-g] hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 4, pp. 1312–1317, 2008. View at Publisher · View at Google Scholar · View at PubMed
  21. K. L. Beebe, T. Block, C. DeBattista, C. Blasey, and J. K. Belanoff, “The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats,” Behavioural Brain Research, vol. 171, no. 2, pp. 225–229, 2006. View at Publisher · View at Google Scholar · View at PubMed